Dempze Nancy E buys $2,562,287 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Dempze Nancy E scooped up 47 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 20,702 shares of Johnson & Johnson which is valued at $2,562,287.Johnson & Johnson makes up approximately 4.41% of Dempze Nancy E’s portfolio.

Other Hedge Funds, Including , Summit Asset Management boosted its stake in JNJ in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 12,101 shares of Johnson & Johnson which is valued at $1,497,741. Johnson & Johnson makes up approx 0.66% of Summit Asset Management’s portfolio.Blume Capital Management reduced its stake in JNJ by selling 33,212 shares or 42.58% in the most recent quarter. The Hedge Fund company now holds 44,791 shares of JNJ which is valued at $5,564,834. Johnson & Johnson makes up approx 5.31% of Blume Capital Management’s portfolio.Atlas Browninc. boosted its stake in JNJ in the latest quarter, The investment management firm added 176 additional shares and now holds a total of 33,500 shares of Johnson & Johnson which is valued at $4,195,205. Johnson & Johnson makes up approx 1.69% of Atlas Browninc.’s portfolio.Benedict Financial Advisors Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 98 additional shares and now holds a total of 52,914 shares of Johnson & Johnson which is valued at $6,602,080. Johnson & Johnson makes up approx 3.81% of Benedict Financial Advisors Inc’s portfolio.

Johnson & Johnson closed down -0.91 points or -0.74% at $122.31 with 64,69,495 shares getting traded on Monday. Post opening the session at $123.12, the shares hit an intraday low of $122.28 and an intraday high of $123.27 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.

Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *